The pharmacokinetics of subcutaneous bolus and continuous infusion azidothymidine (AZT) was studied in rhesus monkeys. Three animals received 100 mg/m2 as a bolus injection both intravenously and subcutaneously, with the order of administration randomly determined. Two animals received a continuous subcutaneous infusion of 25 mg/M2 per h for 12 or 24 h. AZT was measured in plasma by a reverse-phase high-pressure liquid chromatographic assay. Following intravenous bolus administration, AZT elimination was rapid, with a mean half-life of 1.2 h and a mean clearance of 318 ml/min per m2 (range, 200 to 441 ml/min per m2). The bolus subcutaneous dose was rapidly (time to peak concentration, 15 to 30 min) and nearly completely (fraction absorbed, 92%) absorbed without evidence of local tissue toxicity. With continuous subcutaneous infusion of AZT, the steady state was attained within 4 h and steady-state concentrations in plasma in the two animals exceeded 3.0 ,umol/liter. No local tissue toxicity was observed at the infusion site. The subcutaneous route may be a practical alternative to intravenous administration of AZT and deserves further clinical study.
The nucleoside analog azidothymidine (AZT; zidovudine) is a reverse transcriptase inhibitor that causes termination of viral DNA chain elongation. AZT has been shown to block the infectivity and cytopathic effects of human immunodeficiency virus (HIV) in vitro (6) , and in a placebo-controlled clinical trial, AZT significantly lowered both the mortality rate and the frequency of opportunistic infections in patients with symptomatic HIV infection (2) . Although therapeutic drug concentrations in plasma have not been defined, results of in vitro pharmacodynamic studies indicate that continuous exposure to AZT concentrations of 1 p,mol/liter are required to optimally suppress HIV infection (6) .
Because of a pharmacokinetic profile that includes rapid elimination and a short half-life, AZT has been administered intravenously and orally on a schedule of once every 4 h in an attempt to maintain a minimum target concentration in plasma of 1 Local toxicity of subcutaneous injection or infusion of AZT was assessed by careful examination of the site for the 2 weeks following administration of the dose.
Sample analysis. The AZT concentration in plasma was measured by a previously described reverse-phase highpressure liquid chromatographic assay (5) .
Pharmacokinetic calculations. The area under the plasma concentration-time curve (AUC) was derived by using the linear trapezoidal rule and extrapolated to infinity by using the elimination rate constant (3) derived from nonlinear regression analysis of the data with reciprocal weighting by using MLAB. The absolute bioavailability (F) Figure 1 shows the plasma disappearance curves for equal doses of AZT administered both intravenously and subcutaneously to three animals. When administered subcutaneously, AZT was rapidly absorbed and the plasma concentrations were approximately those found following an intravenous dose. The AZT concentration in plasma fell to 1 ,umol/liter by 3 h after the intravenous dose and by 4 h after the subcutaneous dose. The subcutaneous injection site was closely observed for 2 weeks after the dose, and no local toxicity was noted. (1) . The variability in pharmacokinetic parameters exemplified by the twofold range in plasma clearance (Table 1) in three animals is consistent with the variability in AZT disposition observed in humans (la; Balis et al., J. Pediatr., in press). Variability in the bioavailability of the subcutaneous dose (67 to 111%) may also be, in part, related to intra-animal variation in the clearance rate, which is assumed to be constant when calculating absolute bioavailability. This degree of variability suggests that there is a role for therapeutic drug monitoring in patients treated by subcutaneous injection or infusion of AZT, in order to achieve desired concentrations in plasma (la).
RESULTS
AZT only suppresses HIV infection. Human lymphoid cell lines infected with HIV in vitro require continuous exposure to the drug to block the cytopathic effects of the virus (6), and if placed in drug-free medium after prolonged exposure to AZT, the cells rapidly succumb to the virus. Because of the rapid elimination of AZT in vivo, it is difficult to maintain continuous exposure to virostatic concentrations of the drug on an intermittent schedule (5; Balis, et al., J. Pediatr., in press). Results of the in vitro pharmacodynamic studies and the pharmacokinetic profile of AZT suggest that administration of the drug by continuous infusion may be the ideal schedule. A clinical trial (8) and a pharmacokinetic study (la) of AZT administered by continuous intravenous infusion in children has shown that this schedule can produce responses (including dramatic improvement in patients with the acquired immune deficiency syndrome-dementia complex). There is a considerable pharmacokinetic advantage for this approach, which maintains micromolar AZT concentrations in plasma for prolonged periods at a lower dose.
Subcutaneous infusion of AZT may be a practical alternative to continuous intravenous infusion via a central venous catheter. The availability of lightweight, microprocessorbased portable infusion pumps allows for the outpatient administration of long-term subcutaneous and intravenous infusions with minimal disruption in daily schedules; this may actually be more convenient and have better compliance than an around-the-clock, every 4-to 6-h administration schedule. Analgesics and specific agents such as deferoxamine have been successfully administered subcutaneously via portable infusion pumps in chronically ill patients (lb, 4) .
In the primate model, we were able to achieve steady-state concentrations in plasma of greater than 3 ,umol/liter, a concentration that produced unacceptable toxicities in a majority of patients in the continuous infusion study (la). Thus, it should be possible to maintain therapeutic concentrations of AZT by continuous subcutaneous infusion. Clinical studies of this approach are indicated.
